Swedish biotech SME developing patient-specific tissue-engineered veins via decellularization for chronic venous insufficiency treatment.
Verigraft is a Swedish biotech SME developing personalized tissue-engineered blood vessels for clinical use, with a specific focus on veins for patients suffering from chronic venous insufficiency. Their core technology revolves around decellularizing donor blood vessels to remove immunogenic material, then recellularizing them with the patient's own cells to produce a graft the body will not reject. As an SME Instrument Phase 2 coordinator, they are explicitly on a commercialization track — translating a research-grade concept into a manufacturable, clinically deployable product. Their work sits at the intersection of regenerative medicine, vascular surgery, and personalized medicine.
P-TEV (2017–2019) was entirely focused on developing individualized tissue-engineered veins as a treatment for chronic venous insufficiency, coordinated by Verigraft with EUR 2.18M in EC funding.
P-TEV's listed keywords explicitly include 'de-and recellularisation of blood vessels', identifying this as Verigraft's core manufacturing process.
P-TEV targets a specific surgical indication — chronic venous insufficiency — positioning Verigraft's output directly within the vascular surgery clinical pathway.
Participation in Training4CRM (2016–2020), a European Training Network for cell-based regenerative medicine, confirms broader grounding in the regenerative medicine field beyond vascular applications.
Securing an SME Instrument Phase 2 grant (the most competitive EU SME funding tier) for P-TEV signals demonstrated capacity for clinical translation and business case development.
Verigraft entered H2020 funding through Training4CRM (2016), a broad MSCA training network for cell-based regenerative medicine — a participation role with no specific product focus, likely used to build scientific networks and deepen technical knowledge. Within one year they pivoted sharply to coordinating P-TEV (2017), a highly focused SME Phase 2 project with a single commercial objective: a tissue-engineered vein product for a defined patient population. This rapid shift from research network participant to commercial project coordinator, with a 8x increase in funding volume, points to a company that used the training network strategically to prepare for a product development sprint.
Verigraft is on a clear commercialization trajectory — moving from broad regenerative medicine participation toward a single, clinically defined product, suggesting future collaborations will center on clinical validation, regulatory approval, and manufacturing scale-up rather than basic research.
Verigraft operates both as a consortium leader (P-TEV coordinator) and as a strategic participant (Training4CRM), suggesting they know when to drive and when to learn. Their 14 unique partners across 8 countries, achieved in just two projects, indicates an active and deliberate approach to network-building rather than passive consortium membership. As a small SME, they likely function as a technology-focused hub within consortia — bringing the core IP and clinical concept while relying on academic and clinical partners for validation, training, and dissemination.
Verigraft has built a network of 14 unique partners across 8 countries through just two projects, reflecting efficient and purposeful consortium building. Their European reach spans multiple countries typical of health technology and regenerative medicine networks, with likely connections to surgical clinics, academic bioengineering groups, and clinical research organizations.
Verigraft occupies a rare niche: a commercial-stage SME with validated EU funding specifically for personalized vascular tissue engineering — a field where most players are still in academic research. Their SME Instrument Phase 2 status means they passed rigorous EU evaluation of both their technology readiness and their business model, which is strong signal for prospective partners or clients. For any consortium targeting vascular disease, personalized medicine, or advanced therapy medicinal products (ATMPs), Verigraft brings unique product-level expertise that academic partners typically cannot.
